EUVIMEDEUVIMED entdecken
Open Access

First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations

Elizabeth A Suarez, Brian T Bateman, Loreen Straub, Sonia Hernández-Díaz, Hendrée E Jones, Kathryn J Gray, Hilary S Connery, Jonathan M Davis, Barry Lester, Mishka Terplan, Yanmin Zhu, Seanna M Vine und 2 weitere

JAMA Internal Medicine · 01.03.2024 · 184 (3) · 242

DOI: 10.1001/jamainternmed.2023.6986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2024. Verfasst von Elizabeth A Suarez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Buprenorphine, Clubfoot, Foramen Ovale, Patent, Pregnancy Complications. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Use of buprenorphine or methadone to treat opioid use disorder is recommended in pregnancy; however, their teratogenic potential is largely unknown.

Objective

To compare the risk of congenital malformations following in utero exposure to buprenorphine vs methadone. Design, Setting, and Participants This population-based cohort study used health care utilization data from publicly insured Medicaid beneficiaries in the US from 2000 to 2018. A total of 13 360 pregnancies with enrollment from 90 days prior to pregnancy start through 1 month after delivery and first trimester use of buprenorphine or methadone were included and linked to infants. Data were analyzed from July to December 2022. Exposure A pharmacy dispensing of buprenorphine or a code for administration of methadone in the first trimester. Main Outcomes and Measures Primary outcomes included major malformations overall and malformations previously associated with opioids (any cardiac malformations, ventricular septal defect, secundum atrial septal defect/nonprematurity-related patent foramen ovale, neural tube defects, clubfoot, and oral clefts). Secondary outcomes included other organ system–specific malformations. Risk differences and risk ratios (RRs) were estimated comparing buprenorphine with methadone, adjusting for confounders with propensity score overlap weights.

Results

The cohort included 9514 pregnancies with first-trimester buprenorphine exposure (mean [SD] maternal age, 28.4 [4.6] years) and 3846 with methadone exposure (mean [SD] maternal age, 28.8 [4.7] years). The risk of malformations overall was 50.9 (95% CI, 46.5-55.3) per 1000 pregnancies for buprenorphine and 60.6 (95% CI, 53.0-68.1) per 1000 pregnancies for methadone. After confounding adjustment, buprenorphine was associated with a lower risk of malformations compared with methadone (RR, 0.82; 95% CI, 0.69-0.97). Risk was lower with buprenorphine for cardiac malformations (RR, 0.63; 95% CI, 0.47-0.85), including both ventricular septal defect (RR, 0.62; 95% CI, 0.39-0.98) and secundum atrial septal defect/nonprematurity-related patent foramen ovale (RR, 0.54; 95% CI, 0.30-0.97), oral clefts (RR, 0.65; 95% CI, 0.35-1.19), and clubfoot (RR, 0.55; 95% CI, 0.32-0.94). Results for neural tube defects were uncertain given low event counts. In secondary analyses, buprenorphine was associated with a decreased risk of central nervous system, urinary, and limb malformations but a greater risk of gastrointestinal malformations compared with methadone. These findings were consistent in sensitivity and bias analyses. Conclusions and Relevance In this cohort study, the risk of most malformations previously associated with opioid exposure was lower in buprenorphine-exposed infants compared with methadone-exposed infants, independent of measured confounders. Malformation risk is one factor that informs the individualized patient decision regarding medications for opioid use disorder in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineClubfootForamen Ovale, PatentPregnancy ComplicationsOpioid-Related DisordersHeart Defects, CongenitalNeural Tube DefectsHeart Septal Defects, VentricularPregnancyInfantFemaleHumansAdultMethadonePregnancy Trimester, FirstCohort StudiesAnalgesics, Opioid

Substanzen

MethadoneBuprenorphineAnalgesics, Opioid

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey.
  • Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.
  • Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • UNC Horizons Program, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Suarez, E. A., Bateman, B. T., Straub, L., Hernández-Díaz, S., Jones, H. E., Gray, K. J., Connery, H. S., Davis, J. M., Lester, B., Terplan, M., Zhu, Y., Vine, S. M., Mogun, H., & Huybrechts, K. F. (2024). First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations. JAMA Internal Medicine, 184(3), 242. https://doi.org/10.1001/jamainternmed.2023.6986

Vancouver

Suarez EA, Bateman BT, Straub L, Hernández-Díaz S, Jones HE, Gray KJ, et al. First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations. JAMA Internal Medicine. 2024;184(3):242. doi:10.1001/jamainternmed.2023.6986

BibTeX
@article{Suarez2024,
  author = {Suarez, Elizabeth A and Bateman, Brian T and Straub, Loreen and Hernández-Díaz, Sonia and Jones, Hendrée E and Gray, Kathryn J and Connery, Hilary S and Davis, Jonathan M and Lester, Barry and Terplan, Mishka and Zhu, Yanmin and Vine, Seanna M and Mogun, Helen and Huybrechts, Krista F},
  title = {First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations},
  journal = {JAMA Internal Medicine},
  year = {2024},
  volume = {184},
  number = {3},
  pages = {242},
  doi = {10.1001/jamainternmed.2023.6986}
}
Kostenlos starten →